Opinion|Videos|May 8, 2024

Impact of the Introduction of Bispecifics on the Management of Multiple Myeloma

Ke Ning, MD, discusses the impact of the introduction of bispecific antibodies for treating patients with relapsed or refractory multiple myeloma.

Episodes in this series

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.


Latest CME